Introduction to the R&D company and manufacturer of Dali Leisen

Daridorexant is a new type of dual orexin receptor antagonist ( DORA). It is mainly used to treat adult insomnia. It is one of the more advanced sleep aid drugs in the world. The drug was developed by Idorsia Pharmaceuticals Ltd., a Swiss biopharmaceutical company. It is the first central nervous system drug independently developed by Idorsia to enter the international market. Idorsia was originally part of Actelion Pharmaceuticals and was acquired by Johnson & Johnson in 2017. It was subsequently spun off to form an independent company, focusing on the development of high-value innovative drugs, especially in the fields of neurological, cardiovascular and immune diseases.

The R&D code of DaliRasen is ACT-541468. After years of clinical research, it was officially approved by the FDA for marketing in the United States in 2022 under the trade name Quviviq. In the U.S. market, the drug is commercially produced and sold by Idorsia's U.S. subsidiary, marking the company's transformation from a R&D-driven enterprise to a product-oriented enterprise.

In the European market, Daliresin was approved by the European Medicines Agency (EMA) in 2022. It was subsequently gradually launched in countries such as Germany, Italy and the United Kingdom, and was promoted by Idorsia's local branches. At the same time, the company is also promoting the registration and clinical application of this product in Asian markets such as Japan and China, and may accelerate its implementation through licensing cooperation in the future.

In terms of production, the production processes of DaliRasen's raw materials and finished preparations are mainly concentrated in Switzerland and some European countries, and comply with internationalcGMP standards. Preparations are usually provided in tablet form, with common dosages including 25 mg and 50 mg. Each tablet is designed with a strictly controlled release mechanism to maintain effects throughout the night without excessive sedation. Idorsia has also established cooperation with a number of international contract manufacturing organizations (CMOs) to ensure the stability and compliance of its global supply chain.

Reference materials:https://www.quviviq.com/